SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: a comprehensive multidisciplinary team approach

The overexpression of somatostatin receptors on the tumor cell surface of neuroendocrine tumors (NETs) detected by multimodal functional imaging modalities such as SPECT and PET tracers constitutes a therapeutic option using targeting radiolabeled compounds. We will introduce the theranostic concept...

Full description

Saved in:
Bibliographic Details
Published inClinical nuclear medicine Vol. 40; no. 5; p. e271
Main Authors Werner, R A, Bluemel, Christina, Lassmann, M, Kudlich, T, Higuchi, T, Lopci, Egesta, Allen-Auerbach, M, Colletti, Patrick M, Rubello, Domenico, Zatelli, M C, Herrmann, Ken
Format Journal Article
LanguageEnglish
Published United States 01.05.2015
Subjects
Humans
Neuroendocrine Tumors - diagnostic imaging
Neuroendocrine Tumors - radiotherapy
Precision Medicine - methods
Radiopharmaceuticals - therapeutic use
Tomography, Emission-Computed, Single-Photon
Online AccessGet more information

Cover

More Information
Summary:The overexpression of somatostatin receptors on the tumor cell surface of neuroendocrine tumors (NETs) detected by multimodal functional imaging modalities such as SPECT and PET tracers constitutes a therapeutic option using targeting radiolabeled compounds. We will introduce the theranostic concept in general, explain in more detail its development in NETs, and discuss available SPECT and PET tracers regarding their potential for diagnostic imaging, visualization of target expression, and treatment tailoring. Moreover, we will discuss the currently available peptide receptor radionuclide therapy principles and compare them to previously published studies. Finally, we will discuss which new concepts will most likely influence the theranostic treatment approach in NETs in the future.
ISSN:1536-0229
DOI:10.1097/RLU.0000000000000729